237 results
8-K
EX-99.1
IMNN
Imunon Inc
13 May 24
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
8:05am
by the Agency. The Company has begun a Phase 1 proof-of-concept study in two investigational centers. Our goal is to confirm the safety and immunogenicity … interim PFS and OS data with IMNN-001 in its OVATION 2 Study. This study is evaluating the dosing, safety, efficacy and biological activity
8-K
EX-99.1
IMNN
Imunon Inc
8 May 24
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
8:15am
for the study and reporting of data, the potential efficacy and safety profile of our PlaCCine platform, potential partnering opportunities
8-K
EX-99.1
7aqgpvjng f53
28 Mar 24
IMUNON Reports 2023 Financial Results and Provides Business Update
8:05am
8-K
EX-99.1
nqnzoh
14 Nov 23
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.1
jag9tkl
10 Aug 23
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
8:09am
8-K
EX-99.1
fwplreqk
11 May 23
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
8:05am
8-K
EX-99.1
993y3u 4q2yr3s
30 Mar 23
IMUNON Reports 2022 Financial Results and Provides Business Update
8:05am
8-K
EX-99.1
51imc5el39c
15 Nov 22
Third Quarter 2022 Conference Call
9:07am